Cargando…

ML-14 Re-challenge and maintenance therapy of methotrexate for elderly PCNSL patients with low scored KPS

Purpose: The delayed neuronal toxicity after high dose methotrexate (HD-MTX) followed by radiotherapy (RT) is a serious problem for elderly primary CNS lymphoma patients. We started maintenance therapy (MT) with MTX after achieving complete remission (CR) to defer RT for elderly and poor Karnofsky P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamaguchi, Takashi, Nagayama, Rie, Gomi, Akira, Kawai, Kensuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699049/ http://dx.doi.org/10.1093/noajnl/vdaa143.074

Ejemplares similares

ML-13 AN ATTEMPT OF RECHALLENGE OF HD-MTX AND MAINTENANCE THERAPY OF MTX FOR PATIENTS WITH PCNSL
por: Yamaguchi, Takashi, et al.
Publicado: (2019)

ML-11 Tirabrutinib treatment for recurrent or refractory PCNSL
por: Ohka, Fumiharu, et al.
Publicado: (2021)

ML-13 The primary treatment outcomes and future problems of PCNSL elderly patients in our institute
por: Kambe, Atsushi, et al.
Publicado: (2020)

ML-17 Clinical usefulness of Tirabrutinib in recurrent PCNSL: single institute experience
por: Matsuura, Jin, et al.
Publicado: (2021)

ML-15 The future direction of treatment development for primary central nervous system lymphoma (PCNSL)
por: Shinojima, Naoki, et al.
Publicado: (2020)

ML-12 Clinical impact and management of skin-related disorders during treatment of relapsed PCNSL by tirabrutinib
por: Sasaki, Nobuyoshi, et al.
Publicado: (2021)

ML-09 The REAL-WORLD of Elderly PCNSL Therapy in Tohoku and Niigata Area According to Retrospective Analysis: A Collaborative Investigation of the Tohoku Brain Tumor Study Group
por: Asano, Kenichiro, et al.
Publicado: (2020)

ML-07 High expression of PD-L1 on tumor-associated macrophage is a predictive factor for favorable prognosis in PCNSL
por: Furuse, Motomasa, et al.
Publicado: (2020)

ML-04 The influence of surgical intervention for high-dose Methotrexate chemotherapy in the patients with primary central nervous system lymphoma
por: Okamoto, Michinari, et al.
Publicado: (2020)

ML-5 THE TRANSITION OF THE TREATMENT OF 60 PCNSL CASES AT OUR INSTITUTION AND CLINICAL CONSIDERATIONS
por: Yoshitake, Hidenobu, et al.
Publicado: (2022)

ML-4 POLICY CHANGE TO PCNSL TREATMENT LED BY HEMATOLOGY, AND INITIAL TREATMENT RESULTS
por: Hashiba, Tetsuo, et al.
Publicado: (2022)

ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
por: Takezaki, Tatsuya, et al.
Publicado: (2020)

ML-08 THE ROLE OF MAINTENANCE HIGH-DOSE METHOTREXATE CHEMOTHERAPY IN ELDERLY PRIMARY CNS LYMPHOMA PATIENTS
por: Mishima, Kazuhiko, et al.
Publicado: (2019)

Treatment outcome and prognostic factors in PCNSL
por: Niparuck, Pimjai, et al.
Publicado: (2019)

A Comprehensive Evaluation of Possible RNSS Signals in the S-Band for the KPS
por: Han, Kahee, et al.
Publicado: (2022)

ML-12 HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION (HDC-ASCT) FOR THE PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
por: Miyakita, Yasuji, et al.
Publicado: (2022)

ML-4 A case of primary CNS lymphoma diagnosed 5 years after stereotactic radiosurgery
por: Tabei, Yusuke, et al.
Publicado: (2021)

ML-02 Chemotherapy for patients with relapsed or refractory primary CNS lymphoma
por: Nagane, Motoo, et al.
Publicado: (2020)

P1145: PRELIMINARY RESULTS OF PENPULIMAB COMBINED WITH RMA(RITUXIMAB, METHOTREXATE, AND CYTARABINE) FOR NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
por: Shen, Haorui, et al.
Publicado: (2023)

Different imaging patterns of PCNSL and IVL: a case report
por: Jeon, Seung-Ho, et al.
Publicado: (2019)

Liquid Biopsy and Other Non-Invasive Diagnostic Measures in PCNSL
por: Baraniskin, Alexander, et al.
Publicado: (2021)

ML-21 Tirabrutinib monotherapy for relapsed/refractory primary central nervous system lymphoma
por: Kobayashi, Keiichi, et al.
Publicado: (2020)

ML-23 The outcome of malignant lymphoma of the central nervous system in a single institution
por: Kuwahara, Kiyonori, et al.
Publicado: (2020)

PEDT-05 USEFULNESS OF BEVACIZUMAB IN MAINTAINING QOL AT DIPG RELAPSE
por: Gomi, Akira, et al.
Publicado: (2019)

DIPG-02. USEFULNESS OF BEVACIZUMAB IN MAINTAINING QUALITY OF LIFE AT THE TIME OF DIFFUSE INTRINSIC PONTINE GLIOMA RELAPSE
por: Gomi, Akira, et al.
Publicado: (2020)

ML-01 Pathological characteristics of primary central nervous system lymphoma with atypical radiological finding
por: Inukai, Madoka, et al.
Publicado: (2020)

CLRM-15 TRIAL IN PROGRESS: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT INHIBITOR OF BRUTON’S TYROSINE KINASE (BTKI) FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA (R/R PCNSL/SCNSL) AND PRIMARY VITREORETINAL LYMPHOMA (PVRL)
por: Soussain, Carole, et al.
Publicado: (2022)

ML-08 Safety and efficacy of consolidation cytarabine for newly-diagnosed primary central nervous system lymphoma
por: Sasaki, Nobuyoshi, et al.
Publicado: (2020)

GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL
por: Takashima, Yasuo, et al.
Publicado: (2020)

Clinical Efficacy of Image-Guided Radiation Therapy for Cervical Cancer and Its Impact on Patients' Serum Tumor Markers and KPS Scores
por: You, Xin, et al.
Publicado: (2022)

ML-18 Clinical diagnosis for suspected primary central nervous system lymphoma patients without histopathological confirmation
por: Osawa, Sho, et al.
Publicado: (2020)

ML-06 Diagnostic value of liquid biopsy for CNS lymphoma by detection of specific gene mutations in the cerebrospinal fluid
por: Yamagishi, Yuki, et al.
Publicado: (2020)

ML-7 Liquid biopsy for MYD88 mutation in cerebrospinal fluid in patients with suspected primary CNS lymphoma
por: Yuki, Yamagishi, et al.
Publicado: (2021)

ML-13 Primary central nervous system malignant lymphoma in a patient with rheumatoid arthritis receiving tocilizumab
por: Ohno, Masasuke, et al.
Publicado: (2021)

ML-16 First clinical experience of administration of Tirabrutinib for the patients with newly diagnosed primary central nervous system lymphoma
por: Onodera, Sho, et al.
Publicado: (2021)

ML-18 High-dose chemotherapy supported by autologous stem cell transplant in relapsed and refractory primary CNS lymphoma
por: Nagane, Motoo, et al.
Publicado: (2021)

New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL)
por: Gomes Candido Reis, Diego, et al.
Publicado: (2021)

CMS inputs on ML models re-usability
por: Ngadiuba, Jennifer
Publicado: (2022)

Radiation-related thyroid autoimmunity and dysfunction
por: Nagayama, Yuji
Publicado: (2018)

The use of Karnofsky Performance Status (KPS) as a predictor of 3 month post discharge mortality in cirrhotic patients
por: Khalid, Muhammad Ali, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7o226dt0uh3vicofa9mh6i0hka